Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents
- 1 February 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (2), 937-939
- https://doi.org/10.1128/aac.00990-10
Abstract
Efforts to develop novel, interferon-sparing therapies for treatment of chronic hepatitis C (HCV) infection are contingent on the ability of combination therapies consisting of direct antiviral inhibitors to achieve a sustained virologic response. This work demonstrates a proof of concept that coadministration of the nucleoside analogue MK-0608 with the protease inhibitor MK-7009, both of which produced robust viral load declines as monotherapy, to an HCV-infected chimpanzee can achieve a cure of infection.Keywords
This publication has 10 references indexed in Scilit:
- Relapse of hepatitis C in a pegylated‐interferon‐α‐2b plus ribavirin‐treated sustained virological responderHepatology Research, 2010
- MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseAntimicrobial Agents and Chemotherapy, 2010
- Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected ChimpanzeesAntimicrobial Agents and Chemotherapy, 2009
- A transient cell-based phenotype assay for hepatitis C NS3/4A protease: Application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCVJournal of Virological Methods, 2008
- A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic PropertiesAntimicrobial Agents and Chemotherapy, 2004
- Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in VitroJournal of Biological Chemistry, 2003
- Side effects of therapy of hepatitis C and their managementHepatology, 2002
- Side effects of therapy of hepatitis C and their managementHepatology, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998